1 results match your criteria: "North Carolina cTulane National Primate Research Center[Affiliation]"
Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251.
AIDS
February 2017
aAaron Diamond AIDS Research Center, The Rockefeller University, New York City, New York bViiV Healthcare, Research Triangle Park, North Carolina cTulane National Primate Research Center, Covington, Louisiana dGlaxoSmithKline, Research Triangle Park, North Carolina, USA.
Objective: We evaluated the effectiveness of cabotegravir (CAB; GSK1265744 or GSK744) long acting as preexposure prophylaxis (PrEP) against intravenous simian immunodeficiency virus (SIV) challenge in a model that mimics blood transfusions based on the per-act probability of infection.
Design: CAB long acting is an integrase strand transfer inhibitor formulated as a 200 mg/ml injectable nanoparticle suspension that is an effective PrEP agent against rectal and vaginal simian/human immunodeficiency virus transmission in macaques.
Methods: Three groups of rhesus macaques (n = 8 per group) were injected intramuscularly with CAB long acting and challenged intravenously with 17 animal infectious dose 50% SIVmac251 on week 2.